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Dr John S. Ikonomidis (Charleston, SC). I have no relation-
ships to disclose.
Gorav, this was a very interesting presentation. I have several
questions for you.
First, as you mentioned, it is well described that SMCs undergo
apoptosis during aneurysm development. How do you account for
the negative results seen with your animal model as opposed to the
results you saw in the human specimens?
Dr Ailawadi. For the reasons you note, I thought it was impor-
tant to show our caspase-3 data. We have also done Ki-67 staining
to assess proliferation. In our best assessment, the SMC count in
our model appears to be similar, suggesting that the SMCs are pres-
ent but are not expressing these marker genes. In our human sam-
ples, which are advanced lesions, there is loss of SMCs.
Dr Ikonomidis. In that regard, is it possible that the changes that
you are seeing could be explained by a regional heterogeneity phe-
nomenon? In this study you are comparing human ascending aortas
with murine abnormal aortas. Is it possible that there is a body of
evidence that suggests that regional heterogeneity exists within
the aorta, and could that contribute to these results?
Dr Ailawadi. It is certainly possible. We have investigated the
concept of regional heterogeneity in the past, and there do appear
to be differences along the aorta. We did analyze abdominal aortic
aneurysms, and they follow the same pattern, with downregulation
of SMmarker genes in these advanced human lesions that are being
resected as the human ascending aorta. However, we do not have
good control tissue for the abdominal aorta. Normal abdominal aor-
tas in human subjects are difficult to access, and that is why we
chose to use ascending aortas from human subjects as our correlate.
We believe that many of the effector pathways involved in ascend-
ing and abdominal aortas are quite similar.
Dr Ikonomidis. Next, MMP-2 can be produced by multiple cell
types. MMP-9 has been shown in this particular model to be
associated with or produced by the inflammatory infiltrate. You
have shown data that suggest that there is a phenotypic modulation,
and you have also shown data that there is upregulation in MMP-2
and MMP-9 expression. Do you have data that specifically
colocalizes production of MMP-2 and MMP-9 to a unique cell
with a specific phenotype?
Dr Ailawadi. That is the real challenge when we are trying to
correlate modulated SMCs. The way we analyze or identify
SMCs is by their marker genes, and because they lose those marker
genes, it becomes very difficult to assess that this is truly an SMC.
To answer your excellent question requires the use of unique
transgenic mice. These studies are currently underway in our labo-
ratorywith genetically alteredmicewith SMCs that are altered to ex-
press Lac Z, even if they lose their ability to express SM22. Our
preliminary studies demonstrate that SMCs still express MMP-2.
Dr Ikonomidis. The last question I have is that you are making
assertions about a phenotypic change in this study based on changes
in stains for an SMC actin and SM22. Do you have any data on any
more direct surrogates of phenotypic change, for example, KLF-4?
Dr Ailawadi. We are doing several ongoing studies along these
lines. KLF-4 is involved in the pathways of SMC modulation.
Dr Ikonomidis. Again, congratulations on this stimulating
work.ardiovascular Surgery c Volume 138, Number 6 1399
